For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Nikang Therapeutics, Inc.

USPTO Granted Patents = 15

EPO Patents = 3

Trademarks = 1

Forward Citations = 19

Loading Chart...

Loading Chart...

10 inventors (with patents filed for the assignee):

Yan Lou (15 out of 74 patents)

Jiping Fu (14 out of 35 patents)

Yigang He (14 out of 14 patents)

4. Yuetao Shi (2 out of 2 patents)

5. Peng Zhou (2 out of 2 patents)

6. Xingxing Li (2 out of 2 patents)

7. Yan Dong (1 out of 2 patents)

8. Charles M Cook (1 out of 1 patent)

9. Rongzhen Chen (1 out of 1 patent)

10. Jing Lu (0 patent)

15 patents: Sort by Forward Citations

1. 12435034 - Process of preparing 3-fluoro-5(((1R,2AR)-3,3,4,4-tetrafluoro-1,2A-dihydroxy-2,2A,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile (2025-10-07),

2. 12415779 - Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof (2025-09-16),

3. 12391642 - Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors (2025-08-19),

4. 12331026 - Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors (2025-06-17),

5. 12264167 - Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors (2025-04-01),

6. 12171741 - 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors (2024-12-24),

7. 12077506 - Indane derivatives as hypoxia inducible factor-2(α) inhibitors (2024-09-03),

8. 11753366 - Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors (2023-09-12),

9. 11634382 - Process of preparing 3-fluoro-5(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile (2023-04-25),

10. 11518772 - Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors (2022-12-06),

11. 11459340 - Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors (2022-10-04),

12. 11420936 - Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases (2022-08-23),

13. 11267782 - Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2α inhibitors (2022-03-08),

14. 11034705 - Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors (2021-06-15),

15. 10894797 - Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors (2021-01-19),

Company Overview

Nikang Therapeutics, Inc. is a biopharmaceutical company based in Wilmington, Delaware, focused on developing innovative therapies for the treatment of various diseases. The company specializes in the discovery and advancement of novel drug candidates, leveraging cutting-edge research in molecular biology and pharmacology. With a commitment to addressing unmet medical needs, Nikang Therapeutics aims to bring transformative solutions to patients through its robust pipeline and collaborative research efforts.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

15 Patents

#255 in Wilmington, DE

#330 in Delaware

#21,068 in US

#39,959 in the World

Wilmington, DE, United States of America

Nikang Therapeutics, Inc.

Forward Citations = 19

10 inventors:

Yan Lou (15 out of 74 patents)

Jiping Fu (14 out of 35 patents)

Yigang He (14 out of 14 patents)

4. Yuetao Shi (2 out of 2 patents)

5. Peng Zhou (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nikang Therapeutics, Inc.. Retrieved from https://idiyas.com/company/nikang-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…